RITUXAN (also known as Rituximab)
Mechanism:
Rituxan is an antibody directed against CD20 on B lymphocytes and targets problematic cells for destruction.
Indications:
Contraindications:
Patients with active infection should not be started on Rituxan.
Administration:
Rituxan is typically administered as an infusion. For patients with Rheumatoid Arthritis, Rituxan is often initiated and repeated after 2 weeks and then maintained every 24 weeks thereafter.